No Data
No Data
Balancing Potential and Uncertainty: Hold Rating on Amylyx Pharmaceuticals Post-Avexitide Acquisition
Analyst Ratings For Amylyx Pharma
Analysts' ratings for Amylyx Pharma (NASDAQ:AMLX) over the last quarter vary from bullish to bearish, as provided by 5 analysts.The following table summarizes their recent ratings, shedding light on
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Piper
Express News | Goldman Sachs Maintains Neutral on Amylyx Pharma, Raises Price Target to $4
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating
Mizuho Securities analyst Graig Suvannavejh maintains $Amylyx Pharmaceuticals(AMLX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 46.2% and a total average
Amylyx Pharmaceuticals: Holding Steady Amidst Expansion and Market Skepticism